{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T04:47:59Z","timestamp":1789274879500,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinical trials have demonstrated galcanezumab as safe and effective in migraine prevention. However, real-life data are still lacking and overlook the impact of galcanezumab on those different migraine facets strongly contributing to migraine burden. Herein we report the clinical experience from an Italian real-world setting using galcanezumab in patients with migraine experiencing previous unsuccessful preventive treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Forty-three patients with migraine and failure of at least 3 migraine preventive medication classes received monthly galcanezumab 120\u2009mg\u2009s.c. At the first administration and after 3 and 6\u2009months, patients underwent extensive interviews to assess clinical parameters of disease severity. Furthermore, validated questionnaires were administered to explore migraine-related disability, impact, and quality of life as well as symptoms of depression or anxiety, pain catastrophizing, sleep quality and the ictal cutaneous allodynia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After the third and the sixth administration of monthly galcanezumab 120\u2009mg\u2009s.c., headache attacks frequency reduced from 20.56 to 7.44 and 6.37 headache days per month, respectively. Moreover, a significant improvement in headache pain intensity (from 8.95 to 6.84 and 6.21) and duration (from 9.03 to 3.75 and 2.38) as well as in scores assessing migraine related disability and impact, depressive and anxious symptoms, and pain catastrophizing was observed. Furthermore, we demonstrated a significant reduction in the values of \u201cwhole pain burden\u201d, a composite score derived from the product of the average of headache frequency, intensity, and duration in the last three months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Real-world data support monthly galcanezumab 120\u2009mg\u2009s.c. as a safe and effective preventive treatment in reducing headache frequency, intensity, and duration as well as comorbid depressive or anxious symptoms, pain catastrophizing and quality of life in both episodic and chronic migraine patients with previous unsuccessful preventive treatments. Furthermore, we demonstrated that monthly galcanezumab 120\u2009mg\u2009s.c. is able to induce a significant improvement in the scores of \u201cwhole pain burden\u201d. The latter is a reliable and easy-to-handle tool to be employed in clinical setting to evaluate the effectiveness of preventive drugs (in this case, galcanezumab) or when the decision of continuing the treatment with anti-CGRP mAbs is mandatory.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-022-01436-6","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T18:02:29Z","timestamp":1655143349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Galcanezumab effect on \u201cwhole pain burden\u201d and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience"],"prefix":"10.1186","volume":"23","author":[{"given":"Marcello","family":"Silvestro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Tessitore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Orologio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"De Micco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Tartaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Trojsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gioacchino","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"issue":"1","key":"1436_CR1","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s10194-021-01335-2","volume":"22","author":"F Vandervorst","year":"2021","unstructured":"Vandervorst F, Van Deun L, Van Dycke A et al (2021) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain. 22(1):128","journal-title":"J Headache Pain."},{"issue":"5","key":"1436_CR2","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1517\/14740338.2015.1014797","volume":"14","author":"L V\u00e9csei","year":"2015","unstructured":"V\u00e9csei L, Majl\u00e1th Z, Szok D et al (2015) Drug safety and tolerability in prophylactic migraine treatment. Expert Opin Drug Saf 14(5):667\u2013681","journal-title":"Expert Opin Drug Saf"},{"issue":"17","key":"1436_CR3","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","volume":"78","author":"SD Silberstein","year":"2012","unstructured":"Silberstein SD, Holland S, Freitag F et al (2012) Quality standards Subcommittee of the American Academy of neurology and the American headache society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards Subcommittee of the American Academy of neurology and the American headache society. Neurology. 78(17):1337\u20131345","journal-title":"Neurology."},{"issue":"3","key":"1436_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1474-4422(10)70005-3","volume":"9","author":"PJ Goadsby","year":"2010","unstructured":"Goadsby PJ, Sprenger T (2010) Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol 9(3):285\u2013298","journal-title":"Lancet Neurol"},{"issue":"10","key":"1436_CR5","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim BK, L\u00e1inez MJA et al (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19(10):814\u2013825","journal-title":"Lancet Neurol"},{"issue":"9","key":"1436_CR6","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q et al (2018) Evaluation of Galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 75(9):1080\u20131088","journal-title":"JAMA Neurol"},{"issue":"8","key":"1436_CR7","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA et al (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 38(8):1442\u20131454","journal-title":"Cephalalgia."},{"issue":"24","key":"1436_CR8","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S et al (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 91(24):e2211\u2013e2221","journal-title":"Neurology."},{"issue":"1","key":"1436_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s10194-021-01247-1","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, Altamura C, Brunelli N et al (2021) GARLIT study group. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22(1):35","journal-title":"J Headache Pain"},{"issue":"1","key":"1436_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-020-01143-0","volume":"21","author":"A Russo","year":"2020","unstructured":"Russo A, Silvestro M, Scotto di Clemente F et al (2020) Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain. 21(1):69","journal-title":"J Headache Pain."},{"issue":"1","key":"1436_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia. 38(1):1\u2013211","journal-title":"Cephalalgia."},{"issue":"1","key":"1436_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M et al (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 20(1):6","journal-title":"J Headache Pain."},{"issue":"6 Suppl 1","key":"1436_CR13","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1212\/WNL.56.suppl_1.S20","volume":"56","author":"WF Stewart","year":"2001","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J (2001) Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability. Neurology. 56(6 Suppl 1):S20\u2013S28","journal-title":"Neurology."},{"issue":"8","key":"1436_CR14","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/A:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB et al (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12(8):963\u2013974","journal-title":"Qual Life Res"},{"key":"1436_CR15","volume-title":"BDI-II: Beck depression inventory manual","author":"AT Beck","year":"1996","unstructured":"Beck AT, Steer RA, Brown GK (1996) BDI-II: Beck depression inventory manual, 2nd edn. Psychological Corporation, San Antonio","edition":"2"},{"issue":"3","key":"1436_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/1742395312467658","volume":"9","author":"M Worboys","year":"2013","unstructured":"Worboys M (2013) The Hamilton rating scale for depression: the making of a \u201cgold standard\u201d and the unmaking of a chronic illness, 1960-1980. Chronic Illn 9(3):202\u2013219","journal-title":"Chronic Illn"},{"issue":"1","key":"1436_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0165-0327(88)90072-9","volume":"14","author":"W Maier","year":"1988","unstructured":"Maier W, Buller R, Philipp M, Heuser I (1988) The Hamilton anxiety scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord 14(1):61\u201368","journal-title":"J Affect Disord"},{"issue":"5","key":"1436_CR18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.sleep.2008.06.003","volume":"10","author":"RP Allen","year":"2009","unstructured":"Allen RP, Kosinski M, Hill-Zabala CE, Calloway MO (2009) Psychometric evaluation and tests of validity of the medical outcomes study 12-item sleep scale (MOS sleep). Sleep Med 10(5):531\u2013539","journal-title":"Sleep Med"},{"issue":"4","key":"1436_CR19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1046\/j.1526-4610.1998.3804295.x","volume":"38","author":"P Jhingran","year":"1998","unstructured":"Jhingran P, Osterhaus JT, Miller DW et al (1998) Development and validation of the migraine-specific quality of life questionnaire. Headache 38(4):295\u2013302","journal-title":"Headache"},{"key":"1436_CR20","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1212\/01.wnl.0000183358.53939.38","volume":"65","author":"M Jakubowski","year":"2005","unstructured":"Jakubowski M, Silberstein S, Ashkenazi A et al (2005) Can allodynic migraine patients be identified interictally using a questionnaire? Neurology. 65:1419\u20131422","journal-title":"Neurology."},{"issue":"4","key":"1436_CR21","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1037\/1040-3590.7.4.524","volume":"7","author":"MJL Sullivan","year":"1995","unstructured":"Sullivan MJL, Bishop SR, Pivik J (1995) The pain catastrophizing scale: development and validation. Psychol Assess 7(4):524","journal-title":"Psychol Assess"},{"key":"1436_CR22","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"EV Elm","year":"2007","unstructured":"Elm EV, Altman DG, Egger M et al (2007) Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335:806","journal-title":"BMJ"},{"issue":"1","key":"1436_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R et al (2020) Lifting the burden: the global campaign against headache. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 21(1):137","journal-title":"J Headache Pain."},{"issue":"12","key":"1436_CR24","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/j.1468-2982.2009.01874.x","volume":"29","author":"S Cevoli","year":"2009","unstructured":"Cevoli S, D'Amico D, Martelletti P et al (2009) Underdiagnosis and undertreatment of migraine in Italy: a survey of patients attending for the first time 10 headache centres. Cephalalgia. 29(12):1285\u20131293","journal-title":"Cephalalgia."},{"issue":"4","key":"1436_CR25","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1177\/0333102415593086","volume":"36","author":"MT Minen","year":"2016","unstructured":"Minen MT, Loder E, Tishler L, Silbersweig D (2016) Migraine diagnosis and treatment: a knowledge and needs assessment among primary care providers. Cephalalgia. 36(4):358\u2013370","journal-title":"Cephalalgia."},{"issue":"7","key":"1436_CR26","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/head.14154","volume":"61","author":"R Ishii","year":"2021","unstructured":"Ishii R, Schwedt TJ, Dumkrieger G et al (2021) Chronic versus episodic migraine: the 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. Headache. 61(7):992\u20131003","journal-title":"Headache."},{"issue":"3","key":"1436_CR27","first-page":"613","volume":"27","author":"R Burch","year":"2021","unstructured":"Burch R (2021) Preventive migraine treatment. Continuum (Minneap Minn) 27(3):613\u2013632","journal-title":"Continuum (Minneap Minn)"},{"issue":"4","key":"1436_CR28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.ncl.2019.07.004","volume":"37","author":"SK Parikh","year":"2019","unstructured":"Parikh SK, Silberstein SD (2019) Preventive treatment for episodic migraine. Neurol Clin 37(4):753\u2013770","journal-title":"Neurol Clin"},{"issue":"1","key":"1436_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s10194-019-0974-3","volume":"20","author":"TP Do","year":"2019","unstructured":"Do TP, Guo S, Ashina M (2019) Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain. 20(1):37","journal-title":"J Headache Pain."},{"issue":"6","key":"1436_CR30","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1007\/s12325-021-01708-8","volume":"38","author":"P Pozo-Rosich","year":"2021","unstructured":"Pozo-Rosich P, Samaan KH, Schwedt TJ et al (2021) Galcanezumab provides consistent efficacy throughout the dosing interval among patients with episodic and chronic migraine: a post hoc analysis. Adv Ther 38(6):3154\u20133165","journal-title":"Adv Ther"},{"key":"1436_CR31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40263-021-00893-y","volume":"36","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, Fattori D, Benemei S et al (2022) Long-term effectiveness of three anti-CGRP monoclonal antibodies in resistant chronic migraine patients based on the MIDAS score. CNS Drugs 36:191\u2013202","journal-title":"CNS Drugs"},{"issue":"4","key":"1436_CR32","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/jnnp.2009.192492","volume":"81","author":"DC Buse","year":"2010","unstructured":"Buse DC, Manack A, Serrano D et al (2010) Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 81(4):428\u2013432","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"1436_CR33","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10194-012-0479-9","volume":"13","author":"S Ashina","year":"2012","unstructured":"Ashina S, Serrano D, Lipton RB et al (2012) Depression and risk of transformation of episodic to chronic migraine. J Headache Pain. 13(8):615\u2013624","journal-title":"J Headache Pain."},{"issue":"5","key":"1436_CR34","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jpsychores.2015.09.014","volume":"79","author":"MA Louter","year":"2015","unstructured":"Louter MA, Pijpers JA, Wardenaar KJ et al (2015) Symptom dimensions of affective disorders in migraine patients. J Psychosom Res 79(5):458\u2013463","journal-title":"J Psychosom Res"},{"key":"1436_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s10194-016-0649-2","volume":"17","author":"C Lampl","year":"2016","unstructured":"Lampl C, Thomas H, Tassorelli C et al (2016) Headache, depression and anxiety: associations in the Eurolight project. J Headache Pain. 17:59","journal-title":"J Headache Pain."},{"issue":"4","key":"1436_CR36","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/jpr.12162","volume":"59","author":"FS Mortazavi Nasiri","year":"2017","unstructured":"Mortazavi Nasiri FS, Pakdaman S, Dehghani M, Togha M (2017) The relationship between pain catastrophizing and headache-related disability: the mediating role of pain intensity. Jpn Psychol Res 59(4):266\u2013274","journal-title":"Jpn Psychol Res"},{"issue":"3","key":"1436_CR37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/ane.13472","volume":"144","author":"M Silvestro","year":"2021","unstructured":"Silvestro M, Tessitore A, Scotto di Clemente F et al (2021) Refractory migraine profile in CGRP-monoclonal antibodies scenario. Acta Neurol Scand 144(3):325\u2013333","journal-title":"Acta Neurol Scand"},{"key":"1436_CR38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pain.2004.09.033","volume":"113","author":"ML Peters","year":"2005","unstructured":"Peters ML, Vlaeyen JW, Weber WE (2005) The joint contribution of physical pathology, pain-related fear and catastrophizing to chronic back pain disability. Pain. 113:45\u201350","journal-title":"Pain."},{"key":"1436_CR39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/00002508-200106000-00009","volume":"17","author":"R Severeijns","year":"2001","unstructured":"Severeijns R, Vlaeyen JW, van den Hout MA et al (2001) Pain catastrophizing predicts pain intensity, disability, and psychological distress independent of the level of physical impairment. Clin J Pain 17:165\u2013172","journal-title":"Clin J Pain"},{"issue":"12","key":"1436_CR40","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.3390\/ijerph15122648","volume":"15","author":"SJ Kim","year":"2018","unstructured":"Kim SJ, Han KT, Jang SY et al (2018) The association between migraine and types of sleep disorder. Int J Environ Res Public Health 15(12):2648","journal-title":"Int J Environ Res Public Health"},{"issue":"7","key":"1436_CR41","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/j.1526-4610.2005.05159.x","volume":"45","author":"L Kelman","year":"2005","unstructured":"Kelman L, Rains JC (2005) Headache and sleep: examination of sleep patterns and complaints in a large clinical sample of migraineurs. Headache. 45(7):904\u2013910","journal-title":"Headache."},{"issue":"9","key":"1436_CR42","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1111\/j.1526-4610.2010.01711.x","volume":"50","author":"E Sancisi","year":"2010","unstructured":"Sancisi E, Cevoli S, Vignatelli L et al (2010) Increased prevalence of sleep disorders in chronic headache: a case-control study. Headache. 50(9):1464\u20131472","journal-title":"Headache."},{"issue":"24","key":"1436_CR43","doi-asserted-by":"publisher","first-page":"e2224","DOI":"10.1212\/WNL.0000000000008589","volume":"93","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Fanning KM, Buse DC et al (2019) Migraine progression in subgroups of migraine based on comorbidities: results of the CaMEO study. Neurology. 93(24):e2224\u2013e2236","journal-title":"Neurology."},{"issue":"Pt 11","key":"1436_CR44","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1093\/brain\/awt251","volume":"136","author":"MA Louter","year":"2013","unstructured":"Louter MA, Bosker JE, van Oosterhout WP et al (2013) Cutaneous allodynia as a predictor of migraine chronification. Brain. 136(Pt 11):3489\u20133496","journal-title":"Brain."},{"issue":"1","key":"1436_CR45","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-021-01328-1","volume":"22","author":"E Caronna","year":"2021","unstructured":"Caronna E, Gallardo VJ, Alpuente A et al (2021) Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6\u2009months. J Headache Pain. 22(1):120","journal-title":"J Headache Pain."},{"issue":"1","key":"1436_CR46","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s10194-020-01190-7","volume":"21","author":"J Ailani","year":"2020","unstructured":"Ailani J, Andrews JS, Rettiganti M et al (2020) Nicholson RA. Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials). J Headache Pain. 21(1):123","journal-title":"J Headache Pain."},{"issue":"2","key":"1436_CR47","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/03331024211034509","volume":"42","author":"R Gil-Gouveia","year":"2022","unstructured":"Gil-Gouveia R, Oliveira AG (2022) Are PROMs passing the message? A reflection with real-life migraine patients. Cephalalgia 42(2):162\u2013165","journal-title":"Cephalalgia"},{"issue":"6","key":"1436_CR48","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/head.12372","volume":"54","author":"E Cernuda-Moroll\u00f3n","year":"2014","unstructured":"Cernuda-Moroll\u00f3n E, Mart\u00ednez-Camblor P, Ram\u00f3n C et al (2014) CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type a in chronic migraine. Headache. 54(6):987\u2013995","journal-title":"Headache."},{"issue":"1","key":"1436_CR49","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s10194-021-01333-4","volume":"22","author":"S Bottiroli","year":"2021","unstructured":"Bottiroli S, De Icco R, Vaghi G et al (2021) Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study. J Headache Pain. 22(1):114","journal-title":"J Headache Pain."},{"issue":"25","key":"1436_CR50","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJM200006223422507","volume":"342","author":"J Concato","year":"2000","unstructured":"Concato J, Shah N, Horwitz RI (2000) Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342(25):1887\u20131892","journal-title":"N Engl J Med"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01436-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01436-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01436-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T19:02:45Z","timestamp":1655146965000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01436-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1436"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01436-6","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]},"assertion":[{"value":"17 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Ethical Committee of the University of Campania \u201cLuigi Vanvitelli\u201d. The study was conducted according to the ethical principles of the Declaration of Helsinki. Informed consent to participate in the study was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Marcello Silvestro has received speaker honoraria from Lilly, Novartis and Teva. Alessandro Tessitore has received speaker honoraria from Novartis, Schwarz Pharma\/UCB, Lundbeck, Abbvie and Glaxo and serves as an associate editor of European Journal of Neurology. Gioacchino Tedeschi has received speaker honoraria from Sanofi-Aventis, Merck Serono, Bayer Schering Pharma, Novartis, Biogen-Dompe\u00b4 AG; has received funding for travel from Bayer Schering Pharma, Biogen-Dompe\u00b4 AG, Merck Serono, Novartis and Sanofi Aventis; and serves as an associate editor of Neurological Sciences. Antonio Russo has received speaker honoraria from Allergan, Novartis, Lilly and Teva and serves as an associate editor of Frontiers in Neurology (Headache Medicine and Facial Pain session). The other authors have nothing to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}